exoRBase 2.0: an atlas of mRNA, IncRNA and circRNA in extracellular vesicles from human biofluids

Hongyan Lai¹,⁵,†, Yuchen Li¹,⁵,†, Hena Zhang¹,⁵, Jia Hu¹,⁵, Jiatao Liao²,⁵, Ying Su¹,⁵, Qin Li¹,⁵, Bing Chen¹,⁵, Caiping Li³, Zhen Wang¹,⁵, Yan Li¹,⁵, Jialei Wang²,⁵, Zhiqiang Meng¹,⁵,*, Zhaohui Huang⁴,* and Shenglin Huang¹,⁵,*

¹Department of Integrative Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, China, ²Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, ³Department of Gastroenterology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, China, ⁴Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China and ⁵Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Received August 24, 2021; Revised October 15, 2021; Editorial Decision October 18, 2021; Accepted October 21, 2021

ABSTRACT

Extracellular vesicles (EVs) are small membranous vesicles that contain an abundant cargo of different RNA species with specialized functions and clinical implications. Here, we introduce an updated online database (http://www.exoRBase.org), exoRBase 2.0, which is a repository of EV long RNAs (termed exLRs) derived from RNA-seq data analyses of diverse human body fluids. In exoRBase 2.0, the number of exLRs has increased to 19 643 messenger RNAs (mRNAs), 15 645 long non-coding RNAs (lncRNAs) and 79 084 circular RNAs (circRNAs) obtained from ∼1000 human blood, urine, cerebrospinal fluid (CSF) and bile samples. Importantly, exoRBase 2.0 not only integrates and compares exLR expression profiles but also visualizes the pathway-level functional changes and the heterogeneity of origins of circulating EVs in the context of different physiological and pathological conditions. Our database provides an attractive platform for the identification of novel exLR signatures from human biofluids that will aid in the discovery of new circulating biomarkers to improve disease diagnosis and therapy.

INTRODUCTION

Extracellular vesicles (EVs) are nano- to micrometer-sized lipid membrane vesicles (mainly including exosomes and microvesicles) secreted by virtually all cell types (1,2). These vesicles are highly abundant in blood-derived plasma/serum, urine, cerebrospinal fluid (CSF), bile, saliva and other human biofluids (3,4). EVs are widely involved in various physiological and pathological processes through the delivery of different types of bioactive molecules, including nucleic acids (especially RNAs), proteins, lipids and metabolites (5–7). Researchers have devoted substantial efforts to elucidate the biological properties of EV small RNAs (especially microRNAs) and their roles in diseases. Notably, emerging studies have shown that EVs in the circulatory system also contain different long RNA species, including messenger RNA (mRNA), long non-coding RNA (IncRNA) and circular RNA (circRNA) (3,8,9). These EV long RNAs (termed exLRs) are protected from degradation by the bilayer lipid membrane structure and exist stably in human biofluids. ExLRs approximately reflect the intracellular status of their host cells, which implies their potential roles as noninvasive biomarkers for the early detection and therapeutic evaluation of many complex disorders, especially cancers (8,10–12).

The application of advanced high-throughput RNA sequencing (RNA-seq) techniques has enabled researchers to comprehensively characterize the whole transcriptomic profiles of exLRs in large samples. We have developed an optimal strategy (termed exLR-seq) to extract and sequence exLRs, revealed abundant exLRs in human plasma and identified diverse specific markers potentially useful for cancer diagnosis (13,14). By combining exLR expression profiles with a robust algorithm, an EV deconvolution strategy (named EV-origin) was proposed to separately predict the relative and absolute fractions of EVs from blood cells...
and tissues (15). This traceability system makes it possible to decipher the complex heterogeneity of the tissue-cellular origin of circulating EVs. Furthermore, recent reports of EV transcriptomic characterization have also enabled the identification of specific exLRs for glioblastoma multiforme and defined different exLR panels for diagnosing esophageal squamous cell carcinoma and prostate cancer (16–18). Through differential gene expression and pathway enrichment analyses based on exLR profiles, Shi et al. monitored tumor-intrinsic and host immune status and predicted melanoma checkpoint blockade outcome (19). Progress in the study of EV transcriptome has emphasized the need for integrating and comparing the exLR profiles from healthy samples and different cancerous samples.

In 2017, we established exoRBase, a repository of exLRs in human blood exosomes from 92 normal controls and patients with five different cancer types (20). ExoRBase provides users an easy-to-use resource to query the annotation and expression information of exLRs. This database has received >70,000 universal visitors and has been highly cited by researchers. To date, several other databases depositing EV RNAs have also been published. However, these databases only focused on well-studied small RNAs or a small part of exLRs. For example, EVAtlas houses the expression profiles of seven ncRNA types in EV samples from 24 human tissues/diseases (21). LncExpDB documents 1,538 exosomal IncRNAs differentially expressed across diverse biological conditions (22). ExoceRNA was built based on our exoRBase and serves as a repository of competing endogenous RNAs in blood exosomes, which only represent a subset of exoRBase IncRNAs and mRNAs (23).

Here, we introduce a completely expanded version, exoRBase 2.0, which contains 905 exLR-seq data of EVs from four types of human biofluids, including blood, urine, CSF and bile. These biofluid samples were collected from healthy individuals as well as patients with 13 types of cancer or other disease. All exLR-seq data were analyzed using an improved bioinformatics pipeline. The annotation information and expression profiles of 19,643 mRNAs, 15,645 IncRNAs and 79,084 circRNAs in EVs were obtained. We also covered the enrichment scores of 11,536 MSigDB (Molecular Signatures Database) pathways for each sample generated by ssGSEA (single sample Gene set Enrichment Analysis) analyses on exLR expression profiles. In addition, exoRBase 2.0 provides the relative and absolute distribution of 16 types of tissue cells and 23 types of blood cells produced by the modified EV-origin approach. All data and plots in exoRBase 2.0 are freely available for download.

### MATERIALS AND METHODS

#### Integration of available RNA-seq data

We collected a total of 905 RNA-seq data of EVs from human blood, urine, CSF and bile samples, which were compiled into the exoRBase 2.0 database (Table 1). These blood samples were associated with diverse biological conditions, including healthy state, benign disease, breast cancer (BRCA), coronary heart disease (CHD), colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), glioblastoma multiforme (GBM), gastric cancer (GC), kidney cancer (KIRC), hepatocellular carcinoma (HCC), malignant lymphoma (ML), melanoma (MEL), ovarian cancer (OV), pancreatic adenocarcinoma (PAAD) and small cell lung cancer (SCLC). The source of each dataset was listed in the website (http://www.exorbase.org/exoRBaseV2/statistics/index). The latest release (RNA-seq analysis V8) of gene expression TPM profiles (GENCODE version 26) across 30 tissues in the Genotype-Tissue Expression (GTEx) project was also downloaded for annotating possible original tissues of exLRs (24).

| Type        | Cohort          | exoRBase 1.0 | exoRBase 2.0 |
|-------------|-----------------|--------------|--------------|
| Urine       | Urine           | -            | 16           |
| CSF         | CSF             | -            | 5            |
| Bile        | Bile            | -            | 17           |
| Blood       | Healthy         | 32           | 118          |
|             | Benign          | 60           | 130          |
|             | BRCA            | 2            | 140          |
|             | CHD             | 6            | 12           |
|             | CRC             | 12           | 35           |
|             | ESCC            | -            | 6            |
|             | GBM             | -            | 13           |
|             | GC              | -            | 9            |
|             | HCC             | 21           | 112          |
|             | KIRC            | -            | 15           |
|             | ML              | -            | 28           |
|             | MEL             | -            | 21           |
|             | OV              | -            | 30           |
|             | PAAD            | 14           | 164          |
|             | SCLC            | -            | 36           |

| Target | mRNA | 18 333 | 19 643 |
|--------|------|--------|--------|
|        | IncRNA | 15 501 | 15 645 |
|        | circRNA | 58 330 | 79 084 |
|        | Pathway | - | 11 536 |
|        | Tissue/Cell origin | - | 39 |

CSF: cerebrospinal fluid; BRCA, breast cancer; CHD, coronary heart disease; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GBM, glioblastoma multiforme; GC, gastric cancer; KIRC, kidney cancer; HCC, hepatocellular carcinoma; ML, malignant lymphoma; MEL, melanoma; OV, ovarian cancer; PAAD, pancreatic adenocarcinoma; SCLC, small cell lung cancer.

#### Identification, annotation and quantification of exLRs with an improved pipeline

Referring to the ASJA program (Assembling Splice Junctions Analysis, https://github.com/HuangLab-Fudan/ASJA) (25), we employed an improved exLR-seq analysis pipeline to reanalyze the raw sequencing data of all samples (Figure 1). Briefly, the overall quality of raw FASTA files was assessed by FastQC (version 0.11.8) followed by filtering out low-quality reads and removing adapter sequences with the help of Trimmmomatic (version 0.36) (26). The remaining reads were aligned to the human reference genome (GRCh38 from GENCODE) by STAR (version 2.7.1a) in 2-pass mapping mode (27). The reads mapped to regions of protein coding or long non-coding (mRNAs or IncRNAs) genes were counted by featureCounts (version 1.6.3) with an appropriate setting of strand-specific parameter “-s” (28). The read count of each gene was normalized to the TPM (transcripts per million) value as follows: $TPM_i =$

---

**Table 1. Expanded data in exoRBase 2.0 compared with exoRBase 1.0**
Figure 1. A schematic overview of the exoRBase 2.0 core content and framework. ExoRBase 2.0 integrates RNA-seq data of EVs from human blood, urine, CSF, and bile samples. The exLRs, including mRNAs, IncRNAs, and circRNAs, were identified, annotated, and quantified according to the Assembling Splice Junctions Analysis (ASJA) and CircRNA Identifier (CIRI2) bioinformatic tools. To interpret EV mRNA expression profiles, pathway enrichment analysis was performed on MSigDB gene sets using the ssGSEA method. The EV-origin approach was applied to predict the proportions of tissue/blood cell sources. ExoRBase 2.0 visualizes and compares exLR expression profiles as well as the enrichment levels of functional pathways and the origins of circulating EVs.

$$\sum_{i=1}^{\text{genes}} \frac{RC_i}{L_i} \times 10^6$$

where $RC_i$ is the count of reads mapped to gene $i$, and $L_i$ is the length of gene $i$. $N$ denotes the number of all mRNA and IncRNA genes. The circRNAs were identified, annotated, and quantified by the ASJA program (25). Additionally, the CIRI2 (CircRNA Identifier), an improved circRNA detection tool, was also used to recognize circRNAs for filtering false positives (29). The final circRNA set was determined as the circRNAs detected by both ASJA and CIRI2 algorithms. To eliminate the impact of sequencing depth on circRNA data, we calculated the CPM (counts per million) value for each circRNA through the number of reads mapped to a circRNA multiplied by $10^6$ and divided by the total number of mapped reads of a given sample.

The basic gene information for all exLRs was annotated with GENCODE version 29. An exLR detected in at least three blood samples would be annotated as blood exLR, and an exLR detected in at least 1 urine (or CSF, bile) sample was annotated as urine (or CSF, bile) exLR. The minimal expression threshold of exLRs was 0.1 and circRNAs had at least two reads. Based on the GTEx expression atlas (V8 release), the tissue specificity scores of mRNA and IncRNA genes were calculated as the difference between the maximum possible entropy and the Shannon entropy of expression values for a gene in all tissues (30,31). The circBase annotation information of circRNAs was obtained as previously described in exoRBase 1.0.

Pathway enrichment analysis

To investigate pathway-level differences among different cohorts, we downloaded the gene sets annotated with pathways from MSigDB (version 7.2, https://www.gsea-msigdb.org/gsea/msigdb/) (32), including seven major collections: 50 hallmark gene sets (33), 292 BIOCARTEA (34), 186 KEGG (35) and 1554 REACTOME (36) gene sets.
of canonical pathways, 7579 BP (biological process) and 1696 MF (molecular function) gene sets derived from the Gene Ontology (GO) resource (37), and 189 oncogenic signature gene sets of cellular pathways. The ssGSEA method implemented in the R GSVA package was then used to analyze the enrichment scores of these 11 536 MSigDB pathways for each sample based on exoLR expression profiles (38,39).

Enumerating tissue-cellular origin of EVs

The estimation analysis of tissue-cellular source contributions of EVs for each sample was performed using EV-origin (15). This approach implemented the quantification of EVs by combining signature genes of tissues and blood cells with expression profiles of exoLRs. The EV-origin R program was modified and applied to separately predict the relative and absolute fractions of EVs derived from 16 human tissues (including adipose tissue, bladder, brain, colon, esophagus, heart, kidney, liver, lung, muscle, nerve, pancreas, pituitary, skin, small intestine and stomach) and 23 types of blood cells (including red blood cells, platelets, CD8+ naive T cells, central memory CD8+ T cells, effector memory CD8+ T cells, terminal effector CD8+ T cells, mucosal-associated invariant T cells, follicular helper T cells, T regulatory cells, type 1 T-helper cells, type 17 T-helper cells, type 2 T-helper cells, CD4+ naive T cells, naive B cells, plasmablasts, natural killer cells, neutrophils, basophils, terminal effector CD4+ T cells, memory B cells, dendritic cells, monocytes and γδ T cells). Table 2 provides the detailed description of all 39 types of EV origins included in exoRBase 2.0.

Statistical analysis and visualization for homogeneity or heterogeneity of targets

To evaluate the expression patterns of exoLRs in various biofluids among different biological conditions, we calculated the expression frequencies (and corresponding sample numbers) and mean expression values of exoLRs in urine, CSF, and bile samples as well as healthy, benign and tumor blood samples. The mean expression values of exoLRs in different tumor cohorts were also calculated and further visualized using line and heat map charts. The mean enrichment scores of each pathway and mean absolute proportions of each EV source in all cohorts were also calculated and visualized. To characterize the differential expression or enrichment targets, the Mann–Whitney U test was used to separately perform differential analysis between healthy individuals and each disease/tumor cohort. To avoid the impact of sample imbalance on differential analysis, we randomly sampled 35 healthy samples to compare with groups with relatively fewer samples (CHD, CRC, GC, KIRC, ML, OV and SCLC). ExoLRs with |log2FC (fold change)| > 1 and P-value <0.05 were considered significantly differential targets, and the enrichment results from pathway analyses and EV-origin strategy with p-value < 0.05 were also included in this study. For groups with larger sample sizes (benign, BRCA, HCC, PAAD), the q-values (adjusted using the adjusted Benjamini–Hochberg method) of differential targets were <0.05. Box plots were used to exhibit or compare the homogeneous or heterogeneous patterns of exoLRs as well as information on pathways and EV origins across all cohorts. In addition, a cumulative percentage chart and rose polar diagram were used to indicate the relative fractions of 16 tissue or 23 blood cell types of EV origins in each exoLR-seq sample. All statistical analyses and plots in exoRBase 2.0 were generated using R software (version 4.0.2) and ggplot2 (version 3.3.2) and ComplexHeatmap (version 2.4.3) packages.

Database construction

The exoRBase 2.0 database was developed based on Akka 2.6.5 (web server) and MySQL (database server). All data were organized and managed by MySQL (version 5.7.31), an open-source relational database management system. The interface of the website was designed and implemented using the Twirl template engine (version 1.5.0). The query system of this database was configured and handled by Play Slick (version 4.0.2). ExoRBase 2.0 can be successfully accessed by different web browsers, including Internet Explorer, Google Chrome, Firefox and Safari.

Updated database content and user interface

Overall, exoRBase 2.0 focuses on integrating and characterizing the transcriptome data of EVs from human body fluids. A system-level overview of the workflow and kernel data for exoRBase 2.0 is presented in Figure 1. By performing a large-scale integration and bioinformatic analysis of EV exoLR-seq datasets, all expressed exoLRs were identified and annotated. Expression profiles of exoLRs as well as enrichment levels of MSigDB pathways and tissue-cellular origins of EVs are stored in exoRBase 2.0 and can be visualized with different plots.

Expanded data and new features

This updated database contains high-quality exoLR-seq data of EVs in blood, urine, CSF and bile samples from 905 individuals. Compared with the previous version, urine (16 samples), CSF (5 samples) and bile (17 samples) represent novel biofluid types. Moreover, exoRBase 2.0 houses many more blood samples obtained from fifteen groups, including healthy participants (118 samples), patients with benign disease (130 samples), BRCA (140 samples), CHD (12 samples), CRC (35 samples), ESCC (6 samples), GBM (13 samples), GC (9 samples), HCC (112 samples), KIRC (15 samples), ML (28 samples), MEL (21 samples), OV (30 samples), PAAD (164 samples) and SCLC (36 samples). Through RNA-seq analysis, the annotation information and expression profiles of 19 643 mRNAs, 15 645 IncRNAs and 79 084 circRNAs detected in EVs were obtained and compiled into exoRBase 2.0. In particular, this database has added the enrichment scores of 11 536 MSigDB pathways and the relative and absolute enrichment proportions of 39 tissue-cellular components of circulating EVs for each sample, which are generated based on the exoLR expression profiles. Table 1 summarizes the increased data and novel contents in exoRBase 2.0.
Table 2. The detailed description of all traceable tissue/cellular types in exoRBase 2.0

| Tissue/cell name | Full name | Main category | Sub category |
|------------------|-----------|---------------|--------------|
| RBC              | Red blood cells | Blood | HSC (hematopoietic stem cell) |
| Platelet         | Platelet | Blood | HSC (hematopoietic stem cell) |
| CD8 naive        | CD8+ naive T cells | Blood | Adaptive immunity |
| CD8 CM           | Central memory CD8+ T cells | Blood | Adaptive immunity |
| CD8 EM           | Effector memory CD8+ T cells | Blood | Adaptive immunity |
| CD8 TE           | Terminal effector CD8+ T cells | Blood | Adaptive immunity |
| MAIT             | Mucosal-associate invariant T cells | Blood | Innate immunity |
| TFH              | Follicular helper T cells | Blood | Adaptive immunity |
| Treg             | T regulatory cells | Blood | Adaptive immunity |
| Th1              | Type 1 T-helper cells | Blood | Adaptive immunity |
| Th17             | Type 17 T-helper cells | Blood | Adaptive immunity |
| Th2              | Type 2 T-helper cells | Blood | Adaptive immunity |
| CD4 naive        | CD4+ naive T cells | Blood | Adaptive immunity |
| B naive          | Naive B cells | Blood | Adaptive immunity |
| Plasmablasts     | Plasmablasts | Blood | Adaptive immunity |
| NK               | Natural killer cells | Blood | Innate immunity |
| Neutrophils      | Neutrophils | Blood | Innate immunity |
| Basophils        | Basophils | Blood | Innate immunity |
| CD4 TE           | Terminal effector CD4+ T cells | Blood | Adaptive immunity |
| B_Memory         | Memory B cells | Blood | Adaptive immunity |
| DCs              | Dendritic cells | Blood | Innate immunity |
| T gd             | γδ T cells | Blood | Innate immunity |
| Adipose Tissue   | Adipose Tissue | Tissue | Other tissue |
| Bladder          | Bladder | Tissue | Solid organ |
| Brain            | Brain | Tissue | Solid organ |
| Colon            | Colon | Tissue | Solid organ |
| Esophagus        | Esophagus | Tissue | Solid organ |
| Heart            | Heart | Tissue | Solid organ |
| Kidney           | Kidney | Tissue | Solid organ |
| Liver            | Liver | Tissue | Solid organ |
| Lung             | Lung | Tissue | Solid organ |
| Muscle           | Muscle | Tissue | Other tissue |
| Nerve            | Nerve | Tissue | Other tissue |
| Pancreas         | Pancreas | Tissue | Solid organ |
| Pituitary        | Pituitary | Tissue | Solid organ |
| Skin             | Skin | Tissue | Solid organ |
| Small Intestine  | Small Intestine | Tissue | Solid organ |
| Stomach          | Stomach | Tissue | Solid organ |

The enhanced browse, search and detail platform

The web interfaces of exoRBase 2.0 have been redesigned to make it more accessible and user-friendly. The major user interfaces are shown in Figure 2.

Browse pages. In the browse section, there are four web pages for users to browse mRNA, lncRNA, circRNA, Pathway or Tissue/Cell origin (Figure 2A). The browse pages for mRNA, lncRNA and circRNA display exLRs recognized in healthy or cancerous biofluids with their basic gene annotation information, as well as general expression information. Users can browse exLRs in this database with different filter criteria. For example, ‘Sample types’ enables users to browse exLRs expressed in single or multiple human biofluids. Users can select frequently expressed exLRs in all samples using the ‘Detection frequency’ input box or select differentially expressed exLRs in certain cancer types compared with healthy individuals using the ‘Different group’ drop-down box. Furthermore, ‘Gene type’ and ‘Tissue specificity’ offer the selection of tissue-specific expressed mRNAs and/or lncRNAs. Users can click the gene symbol to access to the detailed information of a mRNA or lncRNA and click the related circRNA hyperlink to obtain the circRNAs annotated to the corresponding mRNA or lncRNA gene. On the circRNA page, the novel or annotated circRNAs detected in specific genome regions can be screened based on ‘Gene symbol’ and ‘Region’ options. Clicking the circID and circBase ID displays detailed information on the circRNA contained in exoRBase 2.0 and circBase.

In the newly added two browse pages for Pathway and Tissue/Cell origin, the basic annotation and statistical information of pathways and origins are listed. The ‘Different group’ can be specified to choose significantly differential pathways or EV origins. We also provide the selective browsing of pathways that are recorded as specific ‘MSigDB source’. The 39 EV origins can also be selectively browsed according to the ‘Main category’ or ‘Tissue/Cell type’ annotation information. Clicking the pathway ID or tissue/cell name reveals the detail page for Pathway or Tissue/Cell origin. Users can click the pathway name to view the detailed information in the MSigDB database. We also offer a plot icon for every target to directly connect to the profile graph.

In the browse section, entries can be sorted by each column of the table in ascending or descending order. Users can manually set the number of entries displayed per page (default 10) and directly locate entries of interest by a fast,
Figure 2. The enhanced user interface of exoRBase 2.0. (A) The browse pages for mRNA, lncRNA, circRNA, pathway and tissue/cell origin. (B) The search section with four search pages. (C) The search result page with line and heat map charts and a result table. ‘Tumor mean’, ‘Benign mean’ and ‘Healthy mean’ represent the average expression/enrichment values of blood samples from tumor, benign and healthy cohorts, respectively. ‘Urine mean’, ‘CSF mean’ and ‘Bile mean’ indicate average values for urine, CSF and bile samples, respectively. The ‘Different group’ shows significantly divergent groups compared with healthy individuals. (D) The detail section of each target containing ‘Summary’, ‘Profile’ and ‘Comparison’ pages.
easy search with key words. The whole or filtered browse
tables can be downloaded freely.

Search and results. By clicking the ‘Search’ tab on the
top navigation menu, users will jump to the search section
from any pages (Figure 2B). Users can search their mRNAs,
lncRNAs, circRNAs, pathways or tissue/cell origins of
interest by entering a comma-separated list of gene symbols,
circRNA IDs, pathway IDs/names, or tissue/cell names on
the corresponding search page. A simple search box on the
right side of the top navigator on every page can be used to
query mRNA or lncRNA genes quickly (Figure 2A). For
circRNAs, users can also search for circRNAs annotated
to specific genes by inputting gene symbols. The ‘Advanced
filter’ denotes querying the circRNAs located in specific re-
gions of one chromosome. After clicking the ‘Search’ but-
tton, a search result page that includes two charts and a table
will be displayed (Figure 2C). The columns of the search
result table are the same as those in the browsing table. The
heat map chart and line chart demonstrate the mean TPM
values (or CPM values, ssGSEA scores, absolute propor-
tions) of each mRNA/lncRNA gene (or circRNA, Pathway,
Tissue/Cell origin) across urine, CSF, bile and 15 groups of
blood samples. Both the charts and data can be downloaded
with different formats.

Detail pages. Clicking the gene symbol, circID, pathway
ID or tissue/cell name in both browse and search result ta-
bles will link to the corresponding detail section that cur-
rently includes ‘Summary’, ‘Profile’ and ‘Comparison’ three
pages (Figure 2D). For exLRs, users can view more compre-
hensive and detailed annotation information as well as the
expression frequencies (sample numbers) and mean expres-
sion values in tumor, benign, healthy, urine, CSF and bile
samples from the ‘Summary’ page. On the ‘Profile’ page, the
expression profile of an exLR or the enrichment profile of a
pathway across all biofluid sample groups will be visualized
with a box plot. For an EV origin, both the absolute and
relative enrichment proportion profiles are plotted. Users
can manually select fewer groups of interest to be displayed.
For exLRs, we provide the choice of log2 normalization with
‘Log2(TPM + 1)’ and ‘Log2(CPM + 1)’ boxes. On the ‘Com-
parison’ page, users can explore the difference between two
groups with the Student’s t-test (for groups with few sam-
ple) or Wilcoxon test (for groups with many samples). Simi-
larly, the plots and data are also available for download.

Extended contents and database utility

Application of mining exLR markers. Users can browse
and search all exLRs in exoRBase 2.0 and can also mine
candidate exLR biomarkers of specific biofluid types or
cancer types. For example, the frequently overexpressed
liver-specific mRNA genes in HCC blood samples can be
screened out with the specified options (Sample types with
‘Blood’, Gene type with ‘protein coding gene’, Tissue speci-
ficity with ‘Liver’, Detection frequency with ‘0.5–1’, Differ-
ent group with ‘HCC(up)’) on the browse page (Figure 2A).
The greatly narrowed exLR set might exhibit potential as
biomarkers for discriminating HCC patients from healthy
individuals and can be evaluated and analyzed subsequently
in other ways. More detailed information on each exLR can
be obtained by clicking each gene symbol. In addition, users
can directly query desired single or multiple exLRs on the
search page. For example, the FGB, FGG and GPC3 genes
have been reported as HCC EV-derived mRNA markers for
noninvasive early detection of HCC (40). As a demonstra-
tion, we entered ‘FGB, FGG, GPC3’ into the box on the
search page of mRNA and lncRNA or the simple search
box on any page (Figure 2A, B). The search results include
two charts and one table. The heat map chart provides a
holistic view of the average expression level of the three
exLRs across all cohorts (Figure 2C). By clicking the gene
symbol ‘FGB’, detailed information on FGB can be ob-
tained. From the ‘Summary’ page, we further find that FGB
is frequently expressed in tumor, benign and healthy cohorts
and is detected in most bile samples but in only a few urine
and CSF samples (Figure 3A). The expression profile of
FGB in urine, CSF, bile and 12 groups of blood samples is
presented in Figure 3B. Moreover, the comparison between
HCC and healthy as well as benign samples was performed
using the Wilcox test in the ‘Comparison’ page. The results
show that FGB is significantly upregulated in HCC patients
(Figure 3C, D), which is consistent with previously reported
results (40).

Applications to explore pathways and EV origins. Based
on the exLR expression profiles, we further performed
MSigDB pathway enrichment analysis and estimated the
proportions of potential EV sources using EV-origin ap-
proach. These are two important modules of exoRBase
2.0. This improved database now enables users to study
the homogeneity and heterogeneity of pathways and EV
origins across different groups of biofluid samples. Users
can explore desired pathways or EV origins on the browse
and search pages in a manner similar to that described for
exLRs.

exoRBase 2.0 supports the intuitive visualization not
only of the absolute proportions of tissue/cell origins for
comparison between different cohorts but also of the rel-
ative proportions of tissue/cell origins for comparison be-
tween different tissue/cell origins in each sample. By click-
ing the ‘Origin’ on the navigation bar or the ‘Tissue/Cell
origin’ on the home page, the ‘Relative tissue/cell origin
proportions’ page is displayed (Figure 4A and B). By se-
lecting a dataset of interest (e.g., Healthy) and clicking the
‘Run’ icon, the relative abundances of 16 tissue origins and
23 blood cell origins for the top 20 healthy samples are sep-
arately shown in two cumulative percentage charts. Taking
the chart of blood cell origins as an example (Figure 4C),
the relative proportions of EVs originating from the 23 blood
cells in each healthy sample are presented in different col-
ors, and the lengths of bars represent the levels of blood
cell origins. In the chart, we observe that most healthy sam-
ples have a high percentage of EVs released by platelets. In
addition, all healthy samples are listed in a table under the
charts on this page. Clicking the ‘Tissue cells’ icon or ‘Blood
cells’ icon of a given sample (e.g. Healthy001), a hover page
will appear to display the relative proportions of this sam-
ples with a rose polar chart. Figure 4D suggests that higher
levels of EVs are released by CD4_TE, CD8 naive, mono-
cytes and platelets in the Healthy001 sample.
Figure 3. Detailed information and expression profile of FGB. (A) The ‘Summary’ information of FGB gene in the ‘Detail’ section. (B) The expression landscape of FGB across different groups incorporated into exoRBase 2.0 on the ‘Profile’ page. (C, D) Differential expression analysis of FGB between HCC and healthy/benign cohorts on the ‘Comparison’ page. Abbreviations: CSF, cerebrospinal fluid; BRCA, breast cancer; CHD, coronary heart disease; CRC, colorectal cancer; GC, gastric cancer; KIRC, kidney cancer; HCC, hepatocellular carcinoma; ML, malignant lymphoma; OV, ovarian cancer; PAAD, pancreatic adenocarcinoma; SCLC, small cell lung cancer.
**Figure 4.** The relative proportions of EV origins. (A) The ‘Origin’ tab at the top of each page and the ‘Tissue/Cell origin’ tab on the home page for accessing the relative information obtained from EV-origin method. (B) The ‘Relative tissue/cell origin proportions’ page with selection of the ‘Healthy’ dataset. (C) The relative abundances of 23 types of blood cells in the top 20 healthy samples. (D) The relative abundances of 23 types of blood cells in the Healthy001 sample. In the two charts, the fractions of blood cells in each sample are indicated by different colors, and the lengths of bars indicate the enrichment levels of blood cell populations.
DISCUSSION AND PERSPECTIVES

In this work, we introduce the greatly improved exoRBase 2.0, which documents a large set of exLRs expressed in 905 urine, CSF, bile and blood samples from healthy individuals and patients with benign diseases and tumors. This database enables users to query and visualize the comprehensive annotation information and expression landscapes of exLRs, the enrichment scores of MSigDB pathways and the relative and absolute fractions of tissue and blood cell origins of EVs. ExoRBase 2.0 serves not only as a resource for exLRs but also as a platform for assessing the potential functional changes of exLRs and the heterogeneity of tissue-cellular origins of EVs.

According to the professional practice recommended by the International Society for Extracellular Vesicles (ISEV), nanometer-sized membrane-bound particles (mainly including exosomes and microvesicles) are uniformly named extracellular vesicles (EVs). We followed this nomenclature principle by using the term EVs instead of exosomes in the updated database. ExoRBase 2.0 features several advantages compared with exoRBase 1.0. First, the new version provides a holistic view of EV transcriptomes in diverse human biofluids. Single exLR expression analysis can be performed among more than ten disease/tumor cohorts. Second, exoRBase 2.0 provides an additional opportunity to conduct concordant and differential pathway analysis for interpreting EV mRNA expression data and gaining insights in biological mechanisms. Third, the predicted abundances of EV origins will provide researchers with cellular-level indicators to evaluate the homogeneity and heterogeneity of different cohorts in physiological or pathological conditions. A few issues however should be noted: (i) The expression levels of most exLRs are comparatively low given the low abundance of EVs in human biofluids. Therefore, the expression frequencies are provided and act as additional parameters for expression evaluation. (ii) Compared with blood samples, the sizes of urine, CSF and bile samples are too small. In the future, more attention will be given to obtain exLR-seq data for such biofluids. (iii) The exLR-seq data of ESCC, GBM and MEL blood samples are produced by different teams with low mapped read counts. Hence, these data are only used to annotate exLRs detected in such types of samples, and the differences between the three groups and the healthy group were not taken into consideration. The sample selection criteria will be further refined to reduce the influence of sequencing quality on downstream analysis.

To our knowledge, exoRBase 2.0 remains the only online resource available for exploring different long RNA biotypes of EVs in human normal and cancerous biofluids. Based on these new features, we hope exoRBase 2.0 will be one of the most popular tools to facilitate the identification of novel exLR signatures from human biofluids and to help discover new circulating biomarkers for the improvement of disease diagnosis and therapy. The platform will be updated regularly in the future. We are considering adding exLR data of other biofluids, such as ascites, gastric fluid and saliva. We also encourage researchers to share exLR-seq data of human biofluids in the data submission section to enrich this repository and highlight their discoveries.

ACKNOWLEDGEMENTS

We thank the contributors for providing the RNA-seq datasets. We thank InfinityBio platform for the support on website development.

FUNDING

Shanghai Science and Technology Innovation Action Plan [20JC1419000]; Shanghai Municipal Health Commission [2020CXJQ02]; National Natural Science Foundation of China [81872294, 82072694, 82173063]; Natural Science Foundation of Fujian Province of China [2019J01170]. Funding for open access charge: Shanghai Science and Technology Innovation Action Plan [20JC1419000].

Conflict of interest statement. None declared.

REFERENCES

1. Théry, C., Witwer, K.W., Aikawa, E., Alcara, M.J., Anderson, J.D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G.K. et al. (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles, 7, 1535750.

2. Bordanaba-Florit, G., Royo, F., Kruglik, S.G. and Falcon-Perez, J.M. (2021) Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles. Nat. Protoc., 16, 3163–3185.

3. Murillo, O.D., Thistlewaite, W., Rozowsky, J., Subramanian, S.L., Lucero, R., Shah, N., Jackson, A.R., Srinivasan, S., Chung, A., Laurent, C.D. et al. (2019) exRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids. Cell, 177, 463–477.

4. Hulstaert, E., Morlion, A., Avila Cobos, F., Verniers, K., Neytens, J., Vanden Eynde, E., Yigit, N., Anckaert, J., Geerts, A., Hindryckx, P. et al. (2020) Charting extracellular transcriptomes in the human biofluid RNA atlas. Cell Rep., 33, 108552.

5. Pathan, M., Fonseka, P., Chitti, S.V., Kang, T., Sanwanli, R., Van Deun, J., Hendrix, A. and Mathivanan, S. (2019) Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res., 47, D516–D519.

6. Yañez-Mó, M., Siljander, P.R.M., Andreu, Z., Zavec, A.B., Borrias, F.E., Buzas, E.L., Buzas, K., Casal, E., Cappello, F., Carvalho, J. et al. (2015) Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles, 4, 27066.

7. Russo, F., Di Bella, S., Vannini, F., Berti, G., Scovini, F., Cook, H.V., Santos, A., Nigita, G., Bonnici, V., Lagana, A. et al. (2018) MiRandola 2017: a curated knowledge base of non-invasive biomarkers. Nucleic Acids Res., 46, D354–D359.

8. Vaconcelos, M.H., Cares, H.R., Ábols, A., Xavier, C.P.R. and Liné, A. (2019) Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resist. Updat., 47, 100647.

9. Turchinovich, A., Drapkin, O. and Tonevitsky, A. (2019) Transcriptome of extracellular vesicles: state-of-the-art. Front. Immunol., 10, 202.

10. Porcelli, L., Guida, M., De Summa, S., Di Fonte, R., De Risi, I., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G.K. et al. (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles, 7, 1535750.

11. Tamura, T., Yoshioka, Y., Sakamoto, S., Ichikawa, T. and Ochiya, T. (2021) Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer. Extracell. Vesicles Circ. Nucleic Acids, 2, 148–174.

12. Trino, S., Lamorte, D., Caivano, A., De Luca, L., Sgambato, A. and Laurenzana, I. (2021) Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy. Leukemia, 35, 661–678.

13. Li, Y., Zhao, J., Yu, S., Wang, Z., He, X., Su, Y., Guo, T., Sheng, H., Chen, J., Zheng, Q. et al. (2019) Extracellular vesicles long RNA
sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis. *Clin. Chem.*, **65**, 798–808.

14. Yu,S., Li,Y., Liao,Z., Wang,Z., Wang,Z., Li,Y., Qian,L., Zhao,J., Zong,H., Kang,B. et al. (2020) Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. *Gut*, **69**, 540–550.

15. Li,Y., He,X., Li,Q., Lai,H., Zhang,H., Hu,Z., Li,Y. and Huang,S. (2020) EV-origin: enumerating the tissue-cellular origin of circulating extracellular vesicles using exLR profile. *Comput. Struct. Biotechnol. J.*, **18**, 2851–2859.

16. Re´ategui,E., van der Vos,K.E., Lai,C.P., Zeinali,M., Atai,N.A., Al-Mallak,M., Floyd,F.P., H Khandhel,A., Thapar,V., Hochberg,F.H. et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. *Nat. Commun.*, **9**, 175.

17. Jiao,Z., Yu,A., Rong,W., He,X., Zen,K., Shi,M. and Wang,T. (2020) Five-lncRNA signature in plasma exosomes serves as diagnostic biomarker for esophageal squamous cell carcinoma. *Aging (Albany NY)*, **12**, 15002–15010.

18. Ji,J., Chen,R., Zhao,L., Xu,Y., Cao,Z., Xu,H., Chen,X., Shi,X., Zhu,Y., Lyu,J. et al. (2021) Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer. *Mol. Cancer*, **20**, 58.

19. Shi,A., Kasumova,G.G., Michaud,W.A., Cintolo-Gonzalez,J., Diaz-Martinez,M., Ohmura,J., Mehta,A., Chen,I., Frederick,D.T., Cohen,S. et al. (2020) Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. *Sci. Adv.*, **6**, eabb3461.

20. Li,S., Li,Y., Chen,B., Zhao,J., Yu,S., Tang,Y., Zheng,Q., Li,Y., Wang,P., He,X. et al. (2018) exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res.*, **46**, D106–D112.

21. Liu,C.-J., Xie,G.-Y., Miao,Y.-R., Xia,M., Wang,Y., Lei,Q., Zhang,Q. and Guo,A.-Y. (2021) EVEatlas: a comprehensive database for ncRNA expression in human extracellular vesicles. *Nucleic Acids Res.*, **49**, D962–D968.

22. Li,Z., Liu,L., Jiang,S., Li,Q., Feng,C., Du,Q., Zou,D., Xiao,J., Zhang,Z. and Ma,L. (2021) LncExpDB: an expression database of human long non-coding RNAs. *Nucleic Acids Res.*, **49**, D962–D968.

23. Xu,L., Zhang,L., Wang,T., Wu,Y., Pu,X., Li,M. and Guo,Y. (2020) ExoceRNA atlas: a database of cancer ceRNAs in human blood exosomes. *Life Sci.*, **257**, 118092.

24. The GTEx Consortium. (2020) The GTEx consortium atlas of genetic regulatory effects across human tissues. *Science*, **369**, 1318–1330.

25. Zhao,J., Li,Q., Li,Y., He,X., Zheng,Q. and Huang,S. (2019) ASJA: a program for assembling splice junctions analysis. *Comput. Struct. Biotechnol. J.*, **17**, 1143–1150.

26. Bolger,A.M., Lohse,M. and Usadel,B. (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, **30**, 2144–2142.

27. Dobin,A., Davis,C.A., Schlesinger,F., Drenkow,J., Zaleski,C., Jha,S., Batut,P., Chaisson,M. and Gingeras,T.R. (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, **29**, 15–21.

28. Liao,Y., Smyth,G.K. and Shi,W. (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*, **30**, 923–930.

29. Gao,Y., Zhang,J. and Zhao,F. (2018) Circular RNA identification based on multiple seed matching. *Brief. Bioinform.*, **19**, 803–810.

30. Gersterberger,S., Hafner,M. and Tschili,T. (2014) A census of human RNA-binding proteins. *Nat. Rev. Genet.*, **15**, 829–845.

31. Akat,K.M., Lee,Y.A., Hurley,A., Morozov,P., Max,K.E., Brown,M., Bogardus,K., Sopeyin,A., Hildner,K., Diacovo,T.G. et al. (2019) Detection of circulating extracellular mRNAs by modified small-RNA-sequencing analysis. *JCI Insight*, **5**, e127317.

32. Liberton,A., Subramanian,A., Pinchback,R., Thorvaldsdottir,H., Tamayo,P. and Mesirov,J.P. (2011) Molecular signatures database (MSigDB) 3.0. *Bioinformatics*, **27**, 1739–1740.

33. Liberton,A., Birger,C., Thorvaldsdottir,H., Ghandi,M., Mesirov,J.P. and Tamayo,P. (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.*, **1**, 417–425.

34. Nishimura,D. (2001) BioCarta. *Bioch. Softw. Internet Rep.*, **2**, 117–120.

35. Kanchisa,M., Furumichi,M., Tanabe,M., Sato,Y. and Morishima,K. (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.*, **45**, D353–D361.

36. Jassal,B., Matthews,L., Viteri,G., Gong,C., Lorente,P., Fabregat,A., Sidiropoulos,K., Cook,J., Gillespie,M., Haw,R. et al. (2020) The reactome pathway knowledgebase. *Nucleic Acids Res.*, **48**, D498–D503.

37. The Gene Ontology Consortium (2019) The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res.*, **47**, D330–D338.

38. Barbie,D.A., Tamayo,P., Boehm,JS., Kim,S.Y., Moody,S.E., Dunn,I.F., Schinzler,A.C., Sindy,P., Meylan,E., Scholl,C. et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature*, **462**, 108–112.

39. Hänzelmann,S., Castelo,R. and Guinney,J. (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics*, **14**, 7.

40. Sun,N., Lee,Y.-T., Zhang,R.Y., Kao,R., Teng,P.-C., Yang,Y., Yang,P., Wang,J.J., Smalley,M., Chen,P.-J. et al. (2020) Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. *Nat. Commun.*, **11**, 4489.